🇺🇸 Rabbit antithymocyte globulin in United States

86 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Graft Versus Host Disease — 14 reports (16.28%)
  2. Infection — 11 reports (12.79%)
  3. Hepatotoxicity — 9 reports (10.47%)
  4. Acute Graft Versus Host Disease — 8 reports (9.3%)
  5. Anaemia — 8 reports (9.3%)
  6. Chronic Graft Versus Host Disease — 8 reports (9.3%)
  7. Mucosal Inflammation — 8 reports (9.3%)
  8. Off Label Use — 7 reports (8.14%)
  9. Sepsis — 7 reports (8.14%)
  10. Neutropenia — 6 reports (6.98%)

Source database →

Rabbit antithymocyte globulin in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Rabbit antithymocyte globulin approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Rabbit antithymocyte globulin in United States?

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is the originator. The local marketing authorisation holder may differ — check the official source linked above.